Grafa News and Videos — Page 70

XCF Global (NASDAQ:SAFX) reported more than $10 million in August revenue from renewable diesel shipped from its Reno facility after the site restarted operations in July 2026.

Johnson & Johnson (NYSE:JNJ) reported that TREMFYA met its primary and major secondary endpoints in the Phase 4 STAR study evaluating adults with active psoriatic arthritis and MRI-confirmed axial inflammation.

Legend Biotech (NASDAQ:LEGN) reported five-year results from the Phase 2 CARTITUDE-2 Cohort A study showing that 10 of 20 patients treated with a single CARVYKTI infusion remained alive and progression-free without further anti-myeloma treatment.

Ocugen (NASDAQ:OCGN) announced that OCU400 received provisional approval and priority designation in The Bahamas for the treatment of retinitis pigmentosa, an inherited eye disorder.

C4 Therapeutics (NASDAQ:CCCC) presented new biomarker data from two Phase 1 multiple myeloma combination trials evaluating cemsidomide, including studies with dexamethasone and elranatamab.

Fate Therapeutics (NASDAQ:FATE) received a $15 million grant from the California Institute for Regenerative Medicine to support the Phase 2 RECLAIM-LN clinical trial evaluating FT819, an off-the-shelf CAR T-cell therapy.

Madison Dearborn Partners agreed to acquire The Marygold Companies (NYSE:MGLD) in an all-cash transaction that values each outstanding share at $2.00 and will take the financial services company private.

AstraZeneca (NASDAQ:AZN) received U.S. Food and Drug Administration Priority Review for its supplemental Biologics License Application for IMFINZI (durvalumab) combined with enfortumab vedotin in patients with muscle-invasive bladder cancer who are ineligible for or have declined cisplatin-based chemotherapy.

Johnson & Johnson (NYSE:JNJ) reported five-year CARTITUDE-2 study results showing that 10 of 20 patients treated with CARVYKTI remained alive and progression-free without maintenance therapy after receiving a single infusion.

Merck (NYSE:MRK) and Eisai received U.S. Food and Drug Administration approval for the combination of WELIREG (belzutifan) and LENVIMA (lenvatinib) to treat adults with advanced clear cell renal cell carcinoma after PD-1 or PD-L1 inhibitor therapy.